ACB vs BIOX
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Nov 15, 2026
ACB
BIOX
Investment Advisor Scores
BIOX
AI Analyst Insights
Detailed Metrics Comparison
| Metric | ACB | BIOX | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 109.8901 | 14.9925 | BIOX |
| PEG Ratio | 0 | 1.9521 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | -8.8% | -23.4% | ACB |
| Earnings Growth | -94.7% | 34.4% | BIOX |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 34.9/100 | 60.3/100 | BIOX |
| Profit Margin | -38.2% | -108.5% | ACB |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | EXTENDED | HOLD | Tie |
Relative Price Performance (Last 90 Days)
Current Technical Phase
ACB
MarkupPrice above SMA50, rising 50-day trend (7.4% over 20 days), RSI 64
BIOX
MarkdownPrice below a falling SMA50 (slope -19.1%), weak momentum, RSI 39
Fundamentals Snapshot
| Metric | ACB | BIOX |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -823.3 | 4.2 |
| Trailing P/E | — | — |
| Revenue (TTM) | — | — |
| Revenue Growth | -0.1% | -0.2% |
| Gross Margin | 0.4% | 0.3% |
| Operating Margin | -0.1% | 0.0% |
| EPS | -0.19 | -1.20 |
| Dividend Yield | — | — |